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ABSTRACT
The widespread use of opioids for the treatment of moderate or severe acute and chronic pain has become 
a public health problem due to the physical and psychological dependence and tolerance they produce. 
The increasingly higher doses that patients require may reach toxic levels or lead to accidents, including 
fatalities. 
We present the case of a welder who, while working for a shipping container company, fell from height 
without a safety harness and subsequently died as a result of a traumatic brain injury. Post-mortem exa-
mination revealed a cardiac blood tramadol concentration of 2.83 mg/L, which is 3–4 times higher than 
the maximum therapeutic dose. The combined use of synthetic opioids and antidepressants may heighten 
the adverse neurological and psychiatric effects.
A review of the literature, identified studies, including previous reports of fatalities, supported our causal 
hypothesis of a serotonin syndrome. This syndrome can lead to a loss of cognitive and sensory capacity, 
interfere with decision-making ability, and produce mental confusion and dizziness, among other symp-
toms. In order to prevent harm to themselves and others, all persons who are currently taking these kinds 
of drugs should avoid dangerous tasks at work and must be advised by a physician regarding the type of 
activities that are safe for them to perform.
(Int Marit Health 2020; 71, 2: 109–113)
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INTRODUCTION
The widespread use of opioids, especially for the treat-
ment of moderate or severe acute and chronic pain, has 
become a public health problem in many countries. Notably, 
in the United States, there are increasing reports of fatalities 
among people prescribed these drugs, which produce both 
physical and psychological dependence [1]. In February 2017, 
the Spanish Medicines Agency AEMPS published a report on 
opioid use in our country during the period 2008–2015 [2], 
and data for 2010–2018 [3] are available on the Agency’s 
website. The most widely used active substance in this class is 
tramadol (either alone or in combination with analgesics and 
anti-inflammatory drugs), accounting for 63.2% of prescribed 
analgesic opioids in 2018 [3].
A report published in January 2015 [4] by the Spanish 
Medicines Agency documented a 200% increase in the 
use of antidepressants in Spain during the period 2000–
–2013. The data showed that the most widely used drugs 
of this class were selective serotonin reuptake inhibitors 
(SSRIs), followed by those classified as “other antidepres-
sants”, which accounted, respectively, for 70.4% and 29.7% 
of total antidepressant use in 2013. Although only certain 
antidepressants may interfere with a person’s ability to drive 
and/or carry out potentially dangerous tasks at work, many 
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patients have prescribed them in combination with other 
psychotropic drugs, which increases the associated hazards.
There are only some recommendations by the “Driving 
Under the Influence of Drugs, Alcohol and Medicines” proj-
ect (DRUID) in 2011 [5], on the effects of some medicines 
and driving. That is why, we have produced a guide that 
includes, in addition to driving, the main dangerous work 
activities for the worker himself and for other people [1]. In 
this case report we want to highlight the danger of tramadol.
Just to summarise this case report article. We describe 
the case of a fatal accident involving an employee of a ship-
ping container company in the Port of Barcelona, in which 
the post-mortem examination showed a high blood concen-
tration of tramadol and a concentration within the therapeu-
tic range of venlafaxine.
CASE REPORT
DESCRIPTION OF THE OCCUPATIONAL ACCIDENT
The 41-year-old man had been working for the past 
11 years for a shipping container company in the Port of 
Barcelona. At the time of the occupational accident (8 a.m.) 
he was working in the maintenance terminal of a freight ship-
ping company, where his task was to raise the height of the 
upper gangway allowing access to the straddle carriers. The 
accident occurred while he was preparing the necessary 
material waiting for his work colleague arrival to start the 
task. The steel walkway unexpectedly gave way and, as he 
had not attached a safety harness, he fell from a height of 
12.20 m to the floor of the maintenance terminal.
The emergency paramedics arrived 12 minutes after 
the accident and observed an open fracture of the left fore-
arm, left otorrhagia and a traumatic brain injury. Standard 
resuscitation and treatment procedures were performed 
in situ to stabilise the patient’s vital signs (cervical collar, 
cardio-pulmonary resuscitation manoeuvres and adminis-
tration of 15 mg of Midazolam). Later he was transferred 
by ambulance to the emergency department of a hospital 
in Barcelona (admitted at 9:40 a.m.).
The patient arrives at the Hospital in Coma (grade 3 of 
the Glasgow Coma Scale), hypotension, bradycardia, bilater-
al mydriasis, non-palpable pulses, intraoral blood, bilateral 
otorrhagia. Three litres of Ringer’s serum and 4 vials of 
Beriplex (combination of type II, VII, IX, XI coagulation factors) 
are administered. In a period of 40 minutes, the patient 
progresses to severe bradycardia and asystole, which is 
attempted to be reversed with a defibrillator, but it is not 
successful and the patient dies.
The main autopsy findings are a fracture of the skull 
base, a bilateral pulmonary contusion, and an open fracture 
of the left elbow.
Adams and Hirsch in 1993 published the 5 degrees of 
certainty according to the autopsy findings. Group 1 being 
the most certain and group 5 the least. This case is classified 
in group 1 (the cause of death is identified with the autop-
sy findings with absolute certainty and the mechanism of 
death is structurally demonstrable), these Adams and Hirsch 
grades are well commented by Teijeira et al., 2006 [6].
Biological fluid samples were sent to the toxicology 
laboratory in order to rule out the presence of recreational 
drugs and/or prescribed medicines. The main results of this 
analysis are shown in Table 1.
PERSONAL HISTORY
The man’s medical records, to which access was grant-
ed by a court order, revealed the following information of 
interest. He had suffered from musculoskeletal problems 
for the past 5 years and the initial diagnosis was cervicalgia. 
A year later a diagnosis of cervical osteoarthritis was made, 
and a year prior to the accident he was diagnosed with 
spondylosis (chronic dorsalis). Treatment involved anti-in-
flammatories, muscle relaxants, antidepressants and syn-
thetic opioids. Five years prior to the accident he had been 
prescribed a synthetic opioid (tramadol 37.5 mg/parac-
etamol 325 mg), which he took only sporadically for the first 
3 years, but during the past 2 years he had taken between 
6 and 12 tablets/day. Six months prior to the accident he 
had been prescribed venlafaxine 150 mg/day for reactive 
depression triggered by his chronic pain. He occasionally 
took diazepam 2 mg at night.
The blood tramadol concentration that was detected 
post-mortem is 3–4 higher than the maximum therapeutic 
dose. The analysis was performed using cardiac blood as the 
purpose was to screen for recreational drugs and prescribed 
medicines, although in the specific case of tramadol, testing 
is best performed using femoral blood as the cardiac-to-femo-
Table 1. Results for the main active substances found in blood samples from the deceased*
Active substance Concentration in blood [mg/L] Therapeutic concentration [mg/L]
Tramadol 2.83 0.1–0.8
Venlafaxine 0.05 0.01–0.2
Midazolam** 0.14 0.08–0.25
*A very low blood concentration of diazepam was also detected, 0.01 mg/L (therapeutic value is 0.02–4 mg/L)
**It was subsequently clarified that the paramedics had administered midazolam
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ral blood ratio is 1.4 [7], which in the case of this man would 
imply a femoral blood concentration of tramadol of 2.1 mg/L. 
DISCUSSION
Mainly, in this case, we will refer to the toxicity of tra-
madol, because high concentrations in blood have been 
identified. The rest of the psychotropic drugs concentrations 
were found within the therapeutic values and they can only 
increase the effects of tramadol.
Tramadol is a synthetic opioid receptor agonist that is 
used as an analgesic in cases of moderate or intense pain. 
It is converted in the liver to O-desmethyltramadol and sev-
eral inactive metabolites. The O-desmethyl metabolite, also 
known as M1, is 2–4 times more potent than tramadol itself 
and is primarily responsible for the analgesic effect. Peak 
plasma concentration is reached within 1–2 hours of oral 
administration, and therapeutic blood concentrations are 
in the range 0.1–0.8 mg/L [8]. Tramadol crosses the blood-
brain barrier and has an elimination half-life of 5–6 hours, 
while that of its active metabolite is 7–8 hours. Excretion 
is primarily via the kidneys.
The analgesic effect of tramadol is mainly due to its 
action as an inhibitor of serotonin-norepinephrine reuptake 
in the spinal cord [1, 2]. Accordingly, the most common 
adverse reactions to tramadol are nausea and dizziness, 
which occur in 10% of patients. Among neurological side 
effects, headache and drowsiness are the most frequent, 
although patients may exceptionally experience loss of 
appetite, paraesthesia, tremor, respiratory depression, 
seizures, involuntary muscle spasms, problems with coordi-
nation or syncope. Respiratory depression can occur when 
the dose given is much higher than recommended and 
when the drug is administered simultaneously with other 
central nervous system (CNS) depressants [9]. The most 
common psychiatric symptoms associated with the use of 
tramadol are hallucinations, confusion, sleep disorders 
(including nightmares) and anxiety. The intensity and nature 
of adverse psychological effects varies from one individual 
to another (depending on personality and the duration of 
drug treatment). Impairment of cognitive and sensory abili-
ties (e.g. decision making, altered perception) may also be 
observed. Importantly, tramadol can produce dependence.
The use of tramadol in conjunction with other serotonin-
ergic agents, such as SSRIs, or with monoamine oxidase 
inhibitors may result in a severe serotonin syndrome, which 
in some cases can be fatal. Notably, the patient in the 
present case report was taking tramadol in conjunction 
with venlafaxine (a SSRI). Clarot et al., 2003 [10] examined 
the combined use of tramadol and 21 other drugs and 
concluded that benzodiazepines posed a particular risk. 
Several studies have also documented the neurological 
effects produced by tramadol overdose. 
A study of 190 patients, Marquardt et al., 2005 [11], 
found that 27.4% experienced CNS depression, 5.8% diz-
ziness, 3.7% confusion, 3.2% headache and 1.6% entered 
a coma. Shadnia et al., 2008 [12] examined 114 cases of 
intentional tramadol intoxication and found that 71 (62.3%) 
patients presented vertigo, 40 (35%) had seizures, 31 (27%) 
anxiety and 26 (23.4%) lost consciousness. Finally, a study 
by Spiller et al., 1997 [13] of 87 patients found that the 
symptoms reported with tramadol overdose were lethargy 
in 26 (30%) cases and coma in 4 (5%) patients.
Several studies have also examined fatal intoxications 
involving tramadol. Tjäderborn et al., 2007 [14] analysed 
17 cases of unintentional intoxication and found that blood 
tramadol concentrations at autopsy ranged from 1.1 to 
12 mg/kg. De Decker et al., 2008 [15] described 8 cases 
of fatal intoxication in which tramadol but no other toxic 
substances were detected in blood. Tramadol concentra-
tions ranged between 1.6 and 15.1 mg/L. Simonsen et al., 
2015 [16] conducted an epidemiological study of fatal poi-
soning in drug addicts over a period of three decades in five 
Nordic countries. In Finland during the period 2002–2012, 
deaths due to tramadol accounted for 9–11% of the total 
number of cases.
The blood tramadol concentration that was detected in 
our patient at autopsy is like that reported in several previ-
ous cases. It should be noted that tramadol concentrations 
in cadaveric blood may vary due to post-mortem redistribu-
tion, and in this respect, determinations in femoral blood 
are more reliable [3].
Venlafaxine is an antidepressant that increases neu-
rotransmitter activity in the CNS. Both venlafaxine and its 
main metabolite O-desmethylvenlafaxine are potent inhibi-
tors of serotonin-norepinephrine reuptake. Therapeutic dos-
es of venlafaxine range between 75 and 375 mg/day, and 
peak plasma concentration is reached within 2–3 hours 
of oral administration. The elimination half-life of venla-
faxine is 4–5 hours, while for O-desmethylvenlafaxine it 
is 11 hours.
Adverse neurological effects associated with venlafaxine 
administration include dizziness, headache, paraesthesia, 
sedation and tremor. It may also cause psychiatric symp-
toms such as insomnia, drowsiness, agitation and sleep 
disturbance in the form of nightmares. The concomitant 
use of venlafaxine and tramadol may result in a serotonin 
syndrome involving both central and peripheral neurological 
changes, and fatalities have been reported [17, 18].
It is relevant to notice that medication use is an im-
portant matter to be evaluated from the first and the 
periodical Medical Fitness Examination, especially if the 
worker has to perform dangerous activities. As an exam-
ple, it is clearly included in the Appendix D of the ILO/IMO 
Guidelines on Medical Examination of Seafarers [19], 
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it says “ensure that seafarers are not taking any medi-
cation that has side effects that will impair judgement, 
balance, or any other requirements for effective and safe 
performance of routine and emergency duties on board” 
(STCW Code, Section A-I/9, Paragraph 2.5). The examining 
doctor will need to assess the known adverse effects of 
each medication used and the individual’s reaction to it. 
This is particularly important for those medications that 
are controlled drugs or which may be abused. In the first 
group, we have medications that can impair routine and 
emergency duties like CNS depressants (e.g. sleeping 
tablets, antipsychotics, some analgesics, some anti-anxiety 
and anti-depression treatments and some antihistamines). 
They may need surveillance requirements and restrictions 
to certain type of work, more frequently that full duration 
of the fitness certificate. A follow up of the Occupational 
Health Department and Risk Prevention Services should 
be taken into account.
This fatal occupational accident showed a disconnection 
between the National Health System that controls diseases 
of non-occupational origin and the occupational health 
practitioner in charge of monitoring his health surveillance. 
Normally, only the worker himself, voluntarily, reports his 
health status to his occupational health service. Without 
this knowledge, the occupational doctor cannot adequately 
follow, complete or modify the treatment and propose mod-
ifications or changes in his or her job. The company carries 
out information and training campaigns for its workers, 
regarding specific occupational risks and health promotion. 
But it is needed a better communication system. It is a must 
to show how dangerous, medicines can be, when driving or 
carrying out dangerous work.
CONCLUSIONS
Medication can play an important part in enabling the 
persons to continue to work. And the Occupational Health 
System and the Risk Prevention Department has to be 
aware about, to be able to restrict dangerous work from 
the worker.
In the case reported here, the drugs identified at autopsy 
may have been interfering with the man’s capabilities at the 
time of the accident. Specifically, the concentrations ingested 
and detected in the toxicological analysis could have impaired 
his cognitive and sensory capacity, including his decision-mak-
ing ability and perception of the environment, and they may 
have produced symptoms such as confusion and dizziness. 
In order to prevent harm to themselves and others, all 
persons who are prescribed medication that may impair 
their ability to drive or perform potentially dangerous tasks 
at work must be properly advised by a physician with regard 
to the activities that it is safe for them to carry out.
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